Olmesartan Medoxomil/Amlodipine/Hct Teva (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan medoxomil, the active ingredient in Olmesartan Medoxomil/Amlodipine/HCT Teva, is a combination antihypertensive presented as a tablet for oral use. It treats hypertension in adults by targeting the renin‑angiotensin system, calcium channels, and renal water‑salt balance.

GNH USA supplies Olmesartan Medoxomil/Amlodipine/HCT Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan Medoxomil/Amlodipine/HCT is a combination antihypertensive used to manage elevated blood pressure across several clinical presentations. - Essential hypertension: lowers both systolic and diastolic pressure in patients with primary hypertension. - Isolated systolic hypertension: provides arterial dilation and volume reduction to control high systolic readings. - Hypertension with fluid retention: adds diuretic effect to improve blood pressure control when edema is present.

The following adverse reactions have been reported with the combination product.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate pain often related to blood pressure changes. - Peripheral edema: swelling of the ankles or feet. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Angioedema: rapid swelling of face, lips, tongue, or throat requiring emergency care. - Severe hypotension: marked drop in blood pressure leading to fainting or shock. - Electrolyte imbalance: significant changes in potassium or sodium levels. - Renal impairment: worsening kidney function, especially in patients with pre‑existing disease. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, clinicians should consider several safety factors. - Renal function: monitor serum creatinine and potassium regularly. - Pregnancy: contraindicated (Category D) due to potential fetal harm. - Elderly patients: start at low dose and watch for orthostatic hypotension. - Concomitant potassium‑sparing agents: risk of hyperkalemia, requires monitoring. - Store at ambient temperature: keep in the original container, protect from moisture.

Olmesartan Medoxomil/Amlodipine/HCT may interact with other medicines; some combinations should be avoided while others need close monitoring.

Major Interactions (Avoid): - Aliskiren (in diabetic patients): increased risk of renal failure. - Potassium supplements or ACE inhibitors: heightened risk of hyperkalemia. - Lithium: potential for elevated lithium concentrations.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive effect. - Cyclosporine: can raise serum creatinine levels. - Beta‑blockers: additive hypotensive effect may require dose adjustment.